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Study of Avidity of Antigen-Specific Antibody as a Means of
Understanding Development of Long-Term Immunological Memory
after Vibrio cholerae O1 Infection
Centre for Vaccine Sciences, International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesha; Division of Infectious Diseases, Massachusetts General
Hospital, Boston, Massachusetts, USAb; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USAc; Department of Immunology and Infectious
Diseases, Harvard School of Public Health, Boston, Massachusetts, USAd; Department of Microbiology and Immunobiology, Harvard Medical School, Boston,
Massachusetts, USAe

The avidity of antibodies to specific antigens and the relationship of avidity to memory B cell responses to these antigens have
not been studied in patients with cholera or those receiving oral cholera vaccines. We measured the avidity of antibodies to cholera toxin B subunit (CTB) and Vibrio cholerae O1 lipopolysaccharide (LPS) in Bangladeshi adult cholera patients (n ⴝ 30), as
well as vaccinees (n ⴝ 30) after administration of two doses of a killed oral cholera vaccine. We assessed antibody and memory B
cell responses at the acute stage in patients or prior to vaccination in vaccinees and then in follow-up over a year. Both patients
and vaccinees mounted CTB-specific IgG and IgA antibodies of high avidity. Patients showed longer persistence of these antibodies than vaccinees, with persistence lasting in patients up to day 270 to 360. The avidity of LPS-specific IgG and IgA antibodies in patients remained elevated up to 180 days of follow-up. Vaccinees mounted highly avid LPS-specific antibodies at day 17 (3
days after the second dose of vaccine), but the avidity waned rapidly to baseline by 30 days. We examined the correlation between antigen-specific memory B cell responses and avidity indices for both antigens. We found that numbers of CTB- and LPSspecific memory B cells significantly correlated with the avidity indices of the corresponding antibodies (P < 0.05; Spearman’s
 ⴝ 0.28 to 0.45). These findings suggest that antibody avidity after infection and immunization is a good correlate of the development and maintenance of memory B cell responses to Vibrio cholerae O1 antigens.

V

ibrio cholerae O1 can cause acute watery diarrhea with severe
dehydration in both children and adults and may lead to death
if untreated (1). Natural infection with Vibrio cholerae O1 induces
protection against subsequent symptomatic disease for at least 3 to
7 years (2, 3). Considerable efforts have been made in the last 3
decades to develop safe and effective oral cholera vaccines.
However, the currently available licensed vaccines give protection for between 2 to 3 years, shorter than that following natural infection (4, 5). Several markers of protection against
cholera on exposure, such as plasma IgA against V. cholerae O1
lipopolysaccharide (LPS) (6), vibriocidal antibodies (7, 8), and
memory B cell responses to cholera antigens (9, 10), have been
suggested as potential markers of protective immunity. However, plasma antibody responses decrease in the 6 to 9 months
after cholera, before protective immunity wanes, and while
memory B cell responses persist longer, assay of these responses
is more complicated. It would be helpful in understanding protective immunity to cholera after infection or vaccination if
there was an earlier indicator of subsequent development of
longer-term immunological memory.
In previous studies with patients, we have shown that robust
systemic and mucosal antibodies against lipopolysaccharide
(LPS), cholera toxin B subunit (CTB), and colonization factors,
including the major subunit of the toxin-coregulated pilus
(TcpA), develop after cholera and these may play a role in protection against subsequent infection (11–14). Responses against protein antigens were detectable for a longer period than responses to
the T cell-independent carbohydrate antigen LPS, suggesting that

January 2013 Volume 20 Number 1

T cells may be important for developing and maintaining memory
B cell responses (15).
Antibody avidity, the functional affinity of multivalent antibody to bind multivalent antigen, has been used as a marker of B
cell maturation to discriminate between primary and secondary
responses to a number of infections, including infections with
dengue virus (16), rubella virus (17), (18), cytomegalovirus (19),
and herpesvirus (20). Furthermore, antibody avidity is an important surrogate for determining protective immunity for several
vaccines, including measles vaccine (21), Haemophilus influenzae
type b conjugate vaccine (22), pneumococcal capsular polysaccharide vaccine (23), and mumps vaccine (24). However, studies
on avidity of antibodies generated following cholera and cholera
vaccination have not been reported to date, nor has this been
assessed for other noninvasive infections of the gastrointestinal
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TABLE 1 Characteristics of study participants
Value for groupa
Cholera patients
(n ⫽ 30)

Vaccinees
(n ⫽ 30)

Median age, yr (range)

31 (18–46)

32 (20–45)

Sex, no. (%) of subjects
Male
Female

17 (57)
13 (43)

17 (57)
13 (43)

ABO blood group, no. (%) of subjects
A
B
AB
O

7 (23)
11 (37)
1 (3)
11 (37)

7 (23)
10 (33)
1 (3)
12 (40)

Infecting Vibrio cholerae O1 serotype, no.
Ogawa
Inaba

20
10

NAb
NA

a
b

There were no significant differences between the study groups.
NA, not applicable.

tract. It is also not known if the avidity of antibody responses
correlates with the development and duration of memory B cell
responses.
In this study, we analyzed the avidity of IgG and IgA antibodies
to both a T cell-dependent antigen (CTB) and a T cell-independent antigen (LPS) following natural cholera infection and oral
cholera vaccination, and we correlated these with the development of memory B cell responses recognizing the same antigens.
MATERIALS AND METHODS
Study subjects and specimens. We enrolled adult cholera patients presenting to the hospital of the International Centre for Diarrheal Disease
Research, Bangladesh (ICDDR,B) (9). We also enrolled healthy adults
from an urban field site in Mirpur, Dhaka, Bangladesh, who were given
two doses of the inactivated whole-cell oral cholera vaccine Dukoral at
2-week intervals (25). The healthy volunteers did not take antibiotics in
the past 2 weeks, which was a criterion for enrollment into the study.
Venous blood was collected at the time of enrollment (day 2 for patients
and day 0 for vaccinees) and 3 days after intake of each dose of vaccine;
follow-up blood samples were obtained from patients and vaccinees on
study days 30, 90, 180, 270, and 360 to measure antibody avidity responses
by enzyme-linked immunosorbent assay (ELISA). Specimens from both
the patients with cholera and following cholera vaccination (Table 1)
were used for plasma antibody avidity measurements and for analyses
of memory B cell responses to two key antigens, CTB and LPS (25). The
specimens for this analysis were obtained from Institutional Review
Board (IRB)-approved studies of the Massachusetts General Hospital
and/or ICDDR,B.
Isolation of PBMCs. Peripheral blood mononuclear cells (PBMCs)
and plasma were isolated from heparinized blood diluted with phosphatebuffered saline (PBS) by centrifugation on Ficoll-Isopaque (Pharmacia).
Isolated PBMCs were resuspended to a concentration of 1 ⫻ 107 cells/ml
in RPMI complete medium (Gibco) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (10) and were used for the memory B cell
culture. Plasma was frozen at ⫺70°C for serologic assays.
CTB- and LPS-specific antibodies in patients and vaccinees. Both the
IgG and IgA antibody responses were measured by ELISA using previously described procedures (14, 26). We used 96-well polystyrene plates
(Nunc F; Nunc, Denmark) coated with V. cholerae O1 Ogawa LPS for the
vaccinees (250 ng/well) and the serotype of V. cholerae O1 LPS (Inaba or
Ogawa) homologous to their infecting strain for patients. For the toxin-
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Characteristic

specific responses, plates were coated with ganglioside GM1 (0.3 nmol/
ml), followed by recombinant CTB subunit (50 ng/well) (both gifts from
A. M. Svennerholm, University of Gothenburg, Gothenburg, Sweden).
Then, 100 l of plasma (diluted 1:100 for CTB and 1:25 for LPS in 0.1%
bovine serum albumin in phosphate-buffered saline–Tween) was added
per well, followed by horseradish peroxidase-conjugated secondary antibodies to human IgG or IgA (Jackson ImmunoResearch, West Grove,
PA). Plates were developed with ortho-phenylene diamine (Sigma, St.
Louis, MO) in 0.1 M sodium citrate buffer (pH 4.5) and 0.1% hydrogen
peroxide. Each plate was read kinetically at 450 nm for 5 min; the maximal
rate of change for samples in optical density in milli-absorbance units per
minute was normalized across plates by calculating the ratio of the test
sample value to a standard of pooled convalescent-phase serum from
previously infected cholera patients included on each plate.
Plasma CTB- and LPS-specific IgG and IgA antibody avidity measured by ELISA. Avidity indices for CTB- and LPS-specific plasma IgG
and IgA antibody responses were measured as described earlier (27).
Briefly, 96-well microtiter plates (Nunc F) were coated as described above.
The plates were incubated with two pairs of serially diluted plasma samples (1:5 to 1:2,000 dilution in 0.1% bovine serum albumin–phosphatebuffered saline–Tween) for 90 min at room temperature (RT). The supernatants of the wells were discarded, and one pair of the wells for each
sample was treated with a chaotropic agent, sodium thiocyanate (NaSCN)
(2 M in PBS– 0.3% Tween) for 20 min at RT, whereas the other pair of
wells was treated with PBS– 0.3% Tween alone. After washing with PBSTween, horseradish peroxidase-conjugated anti-human IgG or IgA antibodies (Jackson Laboratories, Bar Harbor, ME) were added at a 1:1,000
dilution, and plates were developed as described above. The optical density (OD) was measured at 492 nm after addition of 1 M sulfuric acid to
the plates. For each patient sample, non-NaSCN-treated wells with an OD
of between 0.5 and 2.0 were used for the calculation of antibody avidity
(28). The avidity index (AI) was calculated as the percentage of the ratio of
measured optical density (OD) in the NaSCN-treated wells to that in the
untreated wells (27) (AI [%] ⫽ OD of NaSCN-treated well ⫻ 100/OD of
non-NaSCN-treated well). A positive-control specimen derived from
pooled, convalescent-phase sera from cholera patients was included on
each ELISA plate (25, 26).
Memory B cell culture and ELISPOT assay. We assessed memory B
cell responses at study initiation (days 0 and 2 in vaccinees and patients,
respectively) and on days 30, 90, 180, 270, and 360 using a previously
described method (9, 10, 29, 30). For this assay, 5 ⫻ 105 cells/well were
cultured in 24-well cell culture plates (BD Biosciences, San Jose, CA)
containing culture medium optimized to stimulate antigen-independent
proliferation and differentiation of memory B cells into antibody-secreting cells (ASCs). The medium consisted of RPMI 1640, 10% FBS, 200 U of
penicillin/ml, 200 g of streptomycin/ml, 2 mM L-glutamine, 50 M ␤-mercaptoethanol, and a mixture of three B cell mitogens, i.e., CpG oligonucleotide (Operon, Huntsville, AL), crude pokeweed mitogen extract, and
fixed Staphylococcus aureus Cowan (Sigma). As a negative control, PBMCs
were also placed into wells containing this culture medium lacking mitogens. The plates were incubated at 37°C in a 5% CO2 incubator for 5 to 6
days, after which the cells were harvested and used to perform antigenspecific (CTB and LPS) and total IgG and IgA enzyme-linked immunospot (ELISPOT) assays. IgG and IgA ASCs were detected using horseradish peroxidase-conjugated mouse anti-human IgG and IgA (Hybridoma
Reagent Laboratory), respectively, followed by development with 3-amino-9-ethyl carbazole (AEC). ELISPOT counts were expressed as the percentage of antigen-specific memory B cells out of the total IgG or IgA
memory B cells in the culture. Wells coated with keyhole limpet hemocyanin (KLH) (Pierce Biotechnology, Rockford, IL) were used as a negative
control. Criteria for inclusion and exclusion of data for analyses were as
described previously (25).
Statistical analyses. Comparisons of the immune responses during
the 1-year follow-up were tested for significance within different study
groups using the Wilcoxon signed rank test and between groups using
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received two doses of cholera vaccine at an interval of 2 weeks apart (day 0 and day 14, indicated by arrows). Bars indicate mean responses, and error bars
represent standard errors of the means. The Wilcoxon signed rank test was used for analyses of data. *, statistically significant difference (P ⬍ 0.05) from the
baseline (day 0 or day 2) titer and the follow-up days indicated.

the Mann-Whitney U test. We also used repeated-measures multivariate analysis of variance (MANOVA) to determine differences between
groups. All reported P values are two sided, with a P value of ⬍0.05
considered a threshold for statistical significance. Spearman’s correlation analysis was used to measure bivariate associations. Analyses were
performed using GraphPad Prism 5.0, SigmaStat 3.1, SPSS 14.0, and
STATA 10.

RESULTS

Study population. Patients admitted to the ICDDR,B hospital
with dehydration were treated with intravenous fluid as well as
with azithromycin. For the patients, the mean duration of stay in
the hospital was 38 h. We enrolled 30 adult cholera patients, both
males (57%) and females (43%), for plasma antibody avidity measurements and for analyses of correlation of avidity with memory
B cell responses to CTB and LPS. Specimens from 30 healthy adult
cholera vaccinees (57% male and 43% female) were also analyzed.
Vaccinees were disease free at the time of specimen collection.
However, during the course of the study we did not follow them
up for illnesses; they were also not admitted to the ICDDR,B diarrheal hospital for any disease during the study period. Details of
the patients and vaccinees are shown in Table 1; the demographic
characteristics of the patients and vaccinees in the study were
comparable. All strains of V. cholerae O1 were of the El Tor biotype and of the altered variant and of both Ogawa and Inaba serotypes. There were no differences in the severity of diarrhea between cholera patients infected with the Ogawa or Inaba serotype
of V. cholerae O1.
CTB- and LPS-specific IgG and IgA antibodies in patients
and vaccinees. An antibody response at any time point was de-
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fined as a significantly higher response than day 2 or day 0 responses for patients and vaccinees, respectively, and both Ogawaand Inaba-infected patients showed comparable responses (P ⬎
0.05). Responses to both CTB and LPS were similar in patients and
vaccinees, although the anti-LPS-specific IgA responses waned
earlier in vaccinees (Fig. 1). The CTB-specific responses lasted
longer than the LPS-specific responses in both patients and vaccinees. This is probably because the response to the protein antigen CTB is T cell dependent whereas that to LPS is T cell independent, resulting in an immune response of shorter duration. The
IgG responses were of higher magnitude than the IgA responses.
Antibody responses peaked at day 30 in patients. In vaccinees,
significant responses were found on day 3, after the first dose of
vaccine (day 0), and these were substantially boosted at day 17,
that is 3 days after intake of the second dose of vaccine (given on
day 14), showing preexistence of CTB- and LPS-specific memory
B cells in the study individuals.
Avidity of CTB-specific antibodies in patients and in vaccinees. The mean CTB-specific IgG antibody avidity index (AI) in
cholera patients on day 2 of infection was 35% ⫾ 1.2%; this increased significantly at day 30 (AI ⫽ 48% ⫾ 2.8%, P ⫽ 0.0002) and
remained elevated throughout the 360 days of follow-up (Fig. 2A).
Prior to vaccination, the CTB-specific IgG AI in healthy adults was
37% ⫾ 1.6%, similar to that in the acute stage in patients. There
was no change in the avidity index at 3 days after intake of the first
dose of vaccine, but the AI increased significantly by day 17
(60% ⫾ 2.8%), after the second dose of vaccine; the AI decreased
gradually and reached baseline levels within 270 days of follow-up.
The CTB-specific IgG AI in patients was significantly higher than
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FIG 1 CTB-specific (A and B) and LPS-specific (C and D) antibody responses in plasma in adult Bangladeshi cholera patients and in vaccine recipients who
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that in vaccinees at days 270 and 360. Similarly, the CTB-specific
IgA AI remained elevated in patients up to day 270 of follow up
(AI ⫽ 42% ⫾ 2.3%; P ⫽ 0.0352), while the AI in vaccinees remained significantly elevated only out to 90 days after vaccination
(AI ⫽ 46% ⫾ 2.2%; P ⫽ 0.0135) (Fig. 2B). Comparable responses
in the CTB-specific IgA were seen at each time point of analysis up
to day 360 (Mann-Whitney U test). However, significant differences in CTB responses were seen between the two groups (P ⬍
0.001) using repeated-measures MANOVA.
LPS-specific avidity responses in patients and vaccinees. On
day 2 of infection, the LPS-specific IgA AI was approximately 39%
in patients; this increased significantly at day 30 (AI ⫽ 49% ⫾
2.4%; P ⫽ 0.0005) and remained elevated up to day 180 postinfection before decreasing to baseline levels (Fig. 2D). The prevaccination LPS-specific IgA AI in healthy adults was 39% (day 0),
similar to that at day 2 in patients. A significantly higher LPSspecific IgA AI (AI ⫽ 48% ⫾ 2.6%; P ⫽ 0.0168) was detectable
only on day 17 in vaccinees but returned to baseline levels by day
30 and beyond (Fig. 2D). The LPS-specific IgA AI was significantly
higher in patients with cholera for up to 180 days following infection than the AI following two doses of vaccination in healthy
Bangladeshi adults. A similar pattern of AIs was observed for LPSspecific IgG. The AI remained elevated up to 180 days following
infection (AI ⫽ 46% ⫾ 1.9%; P ⫽ 0.0014) but was elevated only at
day 17 in vaccinees (Fig. 2C). Compared to that in vaccinees, the
magnitudes of the LPS-specific IgG or IgA AI in patients at days
270 and 360 were comparable, and they waned down to baseline
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on these study days. Using MANOVA, a difference in the IgA but
not the IgG response was seen.
Antigen-specific IgG and IgA memory B cell responses. Statistically significant increases in CTB-specific IgG memory B cell
responses compared to the baseline responses were detected at day
30 in both cholera patients and vaccinees (P ⬍ 0.05) (Fig. 3). The
CTB-specific IgA memory responses were also elevated by day 90
and day 30 in patients and vaccinees, respectively. The memory B
cell response in patients to CTB-specific IgA on day 30 was increased, but this did not reach statistical significance (P ⫽ 0.057),
probably due to the lower numbers of matched data points that
were available for this analysis. In patients, CTB-specific IgG
memory B cell responses persisted for up to 1 year, while the
response waned by day 270 in vaccinees. An anti-CTB-specific IgA
memory B cell response could also be seen at the later stage at day
270 in patients but not in vaccinees. Cholera patients also developed LPS-specific IgA and IgG memory B cell responses that were
significantly elevated by day 30 and day 180, respectively, although
these levels decreased by 360 days (Fig. 3). In comparison, we did
not detect any significant increases of LPS-specific IgA or IgG
memory B cell responses in the vaccine recipients at any time
point.
Correlation between antibody avidity and antigen-specific
memory B cell responses. To determine the correlation between
antibody avidity index and memory B cell responses, we compared avidity indices with memory B cell responses on corresponding days for each antigen and each antibody isotype in both
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FIG 2 Avidity indices of CTB-specific (A and B) and LPS-specific (C and D) antibodies in plasma in Bangladeshi adult cholera patients and in vaccine recipients
who received two doses of cholera vaccine at an interval of 2 weeks (day 0 and day 14). Bars indicate mean responses, and error bars represent standard errors of
the means. The Wilcoxon signed rank test was used for analyses of data. *, statistically significant difference (P ⬍ 0.05) from the baseline (day 0 or day 2) titer to
follow-up indicated above; #, statistically significant difference between cholera patients and vaccinees (P ⬍ 0.05).

Avidity of Antibody to Vibrio cholerae O1

(day 0 and day 14). Memory B cell responses are expressed as percent antigen-specific responses of total isotype-specific memory B cells. Bars represent mean
responses, and error bars represent standard errors of the means. *, statistically significant difference (P ⬍ 0.05) from the baseline (day 0 or day 2) titer; #,
statistically significant difference between cholera patients and vaccinees (P ⬍ 0.05).

patients and vaccinees. Both CTB- and LPS-specific IgG and IgA
avidity indices in patients and vaccinees showed significant positive correlations with corresponding memory B cell responses
(Spearman’s  ⫽ 0.28 to 0.45; P ⬍ 0.05) (Table 2).
DISCUSSION

In this study, we have shown that antibody responses following
cholera and cholera vaccination are robust and develop significant
avidity for both the T cell-dependent antigen cholera toxin and the
T cell-independent antigen lipopolysaccharide. This is the first
TABLE 2 Correlation analyses of antibody avidity index and memory B
cell responses in patients and vaccineesa
Comparisonb
CTB specific
IgG AI and IgG MBC
Patients
Vaccinees
IgA AI and IgA MBC
Patients
Vaccinees
LPS specific
IgG AI and IgG MBC
Patients
Vaccinees
IgA AI and IgA MBC
Patients
Vaccinees
a
b

Spearman’s 

P value

0.350
0.450

⬍0.001
⬍0.001

0.298
0.376

0.012
⬍0.001

0.369
0.373

0.006
⬍0.001

0.283
0.324

0.048
0.001

Spearman’s test was used for correlation analyses.
AI, avidity index; MBC, memory B cell response.
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study that we are aware of that assesses antibody avidity following
a noninvasive mucosal infection, and we show that not only IgG
but also IgA antibodies develop significant avidity. We also show
that antibody avidity measurements correlate with memory B cell
responses to the same antigen at the same time point, consistent
with both of these responses developing in parallel during B cell
maturation following antigen exposure.
Memory B cells are a major component of antibody-mediated
long-term protective immunity following infection or vaccination. For T cell-dependent antigens, memory B cell development
and differentiation occur in germinal centers (GC) of secondary
lymphoid tissue (31). Upon exposure to an antigen, antigen-presenting cells such as dendritic cells present epitopes of that antigen
to CD4⫹ helper T cells, leading to the differentiation of these CD4
T cells into T follicular helper cells (Tfh), which migrate into the
GC of intestinal Peyer’s patches and mesenteric lymph nodes.
These Tfh, characterized by expression of CXCR5, interact in GC
with B cells that recognize that epitope, leading to proliferation of
the B cell with somatic hypermutation and isotype switching. One
result of this proliferation and maturation is the production of
plasma cells (both short- and long-lived) of higher antibody affinity after negative selection in the GC of low-affinity antibodyproducing B cells (31, 32). The other result of this proliferation
and maturation process is the generation of memory B cells that
can play a role in subsequent protective immunity (29). We have
recently shown that early T cell responses to CTB following either
cholera or cholera vaccination correlate well with subsequent
memory B cell responses, consistent with the sequential events
outlined above for maturation of the B cell responses for T celldependent antigens (33). Generation of highly avid IgG antibodies
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FIG 3 CTB and LPS memory B cell responses in Bangladeshi adult cholera patients and vaccinees who received two doses of cholera vaccine separated by 2 weeks
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against V. cholerae O1 infection, which is largely associated with
anti-LPS antibody responses. Also, the level of serum IgA specific
to LPS was found to be associated with protection against cholera
(6). In this study, we showed that patients and vaccinees develop
highly avid antibodies to both CTB and LPS, although the CTBspecific IgG or IgA antibodies with high affinity persisted for longer time period than those to LPS. It is possible that protective
efficacy studies using measurements of antibody avidity to LPS
may show some correlation in the future. This study was carried
out in a country where cholera is endemic, Bangladesh, where
infection with V. cholerae and enterotoxigenic Escherichia coli
(ETEC) is prevalent. Individuals are preexposed to the different
antigens and hence can have preexisting memory B cells. In this
study, we have seen significant increases of CTB- and LPS-specific
IgG and IgA antibody responses in vaccinated individuals on day 3
after the first dose of vaccine conferring preexisting memory B
cells in the study participants.
In summary, our results show that both cholera patients and
those receiving a killed, oral cholera vaccine develop highly avid
antibodies of both the IgG and IgA isotypes to both the T celldependent antigen CTB and the T cell-independent antigen LPS
and that the avidity indices of these antibody responses correlate
well with measurement of memory B cell responses at corresponding time points, suggesting that both events may be occurring as
part of B cell proliferation and maturation. Patients with cholera
have a longer duration of highly avid antibodies and of memory B
cells to both antigens, particularly to the T cell-independent antigen LPS, than do individuals receiving the cholera vaccine, consistent with the shorter duration of protection afforded by the
vaccine. Improved understanding of all the events leading to B cell
maturation to T cell-independent antigens in gut mucosa and the
lamina propria may provide additional insights of relevance to
improving the duration of protection obtained from current cholera and other mucosal vaccines. Antibody avidity may also provide a simpler and more widely available assay for measuring B cell
proliferation and maturation events after infection and vaccination than the current memory B cell assay.
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